1 July

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:00
  [Series] Diagnosis of thyroid nodules - Erik K Alexander, Edmund S Cibas Lancet Diab Endocrinol
  Thyroid nodules are common, usually asymptomatic, and often pose minimal risk to the affected patient. However, 10–15% prove malignant and serve as the rationale for diagnostic assessment. Safely identifying and treating a relevant thyroid cancer through a cost-effective process is the primary (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))
• 00:00
  [Series] Management of thyroid nodules - Erik K Alexander, Gerard M Doherty, Justine A Barletta Lancet Diab Endocrinol
  In the past 30 years, there has been a substantial rise in the detection of thyroid nodules. Largely asymptomatic, thyroid nodules are most often incidental findings that typically pose minimal risk. Data supporting these findings show a rapid rise in the incidental detection of thyroid nodules (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))

9 June

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Editorial] Prioritising COVID-19 over everything: the unintended harm - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  During the past 2 and a half years, countries worldwide saw disruptions in their health-care services as they redirected their efforts and resources to manage the COVID-19 pandemic. At the same time, many people with underlying conditions limited their interactions with others unless necessary, (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))

2 June

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] How should endocrinologists diagnose and treat non-alcoholic fatty liver disease? - Christopher D Byrne, Giovanni Targher Lancet Diab Endocrinol
  Non-alcoholic fatty liver disease (NAFLD) was first described in 1980 in a report from the Mayo Clinic that described the characteristics of non-alcoholic steatohepatitis in 20 patients.1 A liver biopsy showed “the presence of striking fatty changes with evidence of lobular hepatitis, focal (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))
• 00:30
  [In Focus] Diabetes in humanitarian crises - Talha Burki Lancet Diab Endocrinol
  As of May 31, 2022, an estimated 14 million Ukrainians had fled their homes since the Russia invasion earlier in the year. There are no guarantees that they will be able to return anytime soon. Refugees commonly spend years, sometimes decades, away from home. The war in Ukraine has pushed the (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))
• 00:30
  [Correspondence] Cross-sectional associations between the gut microbe Ruminococcus gnavus and features of the metabolic syndrome - Louise Grahnemo, Maria Nethander, Eivind Coward, Maiken Elvestad Gabrielsen, Satya Sree, Jean-Marc Billod, Lars Engstrand, Sanna Abrahamsson, Arnulf Langhammer, Kristian Hveem, Claes Ohlsson Lancet Diab Endocrinol
  It is well established that the gut microbiota influences obesity in mice. In humans, some gut microbes have been associated with obesity, 1,2 but results have been difficult to replicate, proposedly due to small studies and confounders.3,4 Insufficient control over medication use can interfere (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))
• 00:30
  [In Focus] Europe's obesity burden on the rise: WHO report - Vijay Shankar Balakrishnan Lancet Diab Endocrinol
  According to a report from WHO's Regional Office for Europe, released on May 3, 2022, the European region (comprising 53 countries in Europe and Central Asia) exhibits rates of overweight and obesity that are close to those in the Americas. “Obesity knows no borders [and] in Europe and Central (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))

1 June

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:00
  [Correspondence] Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence - Olivier Chabre, Marie Muller, Justine Cristante, Jean-Luc Cracowski, Emmanuel Gay Lancet Diab Endocrinol
  We read with interest the consensus statement of the Pituitary Society on diagnosis and management of Cushing's disease,1 which provides very useful new recommendations, including on neurosurgical or medical treatment of Cushing's disease. We have a comment on table 2, which summarises the (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))
• 00:00
  [Correspondence] Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence – Authors' reply - Maria Fleseriu, Frederic Castinetti, Mônica Gadelha, Andrea Giustina, André Lacroix, Shlomo Melmed, John Newell-Price, Rosario Pivonello, Martin Reincke, Beverly M K Biller, “Consensus on diagnosis and management of Cushing's disease: a guideline update” Lancet Diab Endocrinol
  We thank Olivier Chabre and colleagues for their thoughtful comments on our Review.1 (The Lancet Diabetes & Endocrinology 10, 6 (2022))

28 May

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [In Focus] Treating diabetes: combining tradition and science - Manjulika Das Lancet Diab Endocrinol
  In April, 2022, the foundation stone of the WHO Global Centre for Traditional Medicine, the first and only global outpost centre in the world for traditional medicine, was laid by the Prime Minister of India, Narendra Modi, in Jamnagar, Gujarat, India. Others in attendance included the Indian (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))

27 May

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [In Focus] Sylvia Kehlenbrink: facing the extremes - Carl Power Lancet Diab Endocrinol
  Managing a non-communicable disease (NCD) like diabetes is hard enough in a country with good health care. It is much more difficult where resources are scarce. Add a conflict, a natural disaster, or a humanitarian crisis, and a perfectly treatable illness can become an implacable agent of (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))

17 May

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] The current state of clinical islet transplantation - Rainer W G Gruessner Lancet Diab Endocrinol
  In The Lancet Diabetes & Endocrinology, Braulio Marfil-Garza and colleagues report 20-year outcomes after islet transplantation in a large cohort study.1 It is yet another landmark study by the Edmonton group. In 2000, the so-called Edmonton protocol ushered in a new era in islet (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))
• 00:30
  [Articles] Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada - Braulio A Marfil-Garza, Sharleen Imes, Kevin Verhoeff, Joshua Hefler, Anna Lam, Khaled Dajani, Blaire Anderson, Doug O'Gorman, Tatsuya Kin, David Bigam, Peter A Senior, A M James Shapiro Lancet Diab Endocrinol
  We present the largest single-centre cohort study of long-term outcomes following islet transplantation. Although some limitations with our study remain, such as the retrospective component, a relatively small sample size, and the absence of non-transplant controls, we found that the combined (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))

14 May

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Bone fragility in type 1 diabetes: new insights and future steps - Nicola Napoli, Caterina Conte Lancet Diab Endocrinol
  Bone fragility is a recognised complication of type 1 diabetes.1 People with type 1 diabetes have lower bone mineral density (BMD) and greater fracture risk than individuals without diabetes (more than five times for hip fracture and two times for non-vertebral fractures).2 The mechanisms (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))
• 00:30
  [Articles] Risk factors for lower bone mineral density in older adults with type 1 diabetes: a cross-sectional study - Ann V Schwartz, Jye-Yu C Backlund, Ian H de Boer, Mishaela R Rubin, Annette Barnie, Kaleigh Farrell, Victoria R Trapani, Naina Sinha Gregory, Amisha Wallia, Ionut Bebu, John M Lachin, Barbara H Braffett, Rose Gubitosi-Klug, the DCCT/EDIC Research Group Lancet Diab Endocrinol
  Poorer glycaemic control, AGE accumulation, and kidney disease are independent risk factors for lower hip BMD in older adults with type 1 diabetes. Maintenance of glycaemic control and prevention of kidney disease might reduce bone loss and ultimately fractures in this population. Osteoporosis (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))

7 May

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Is autonomous cortisol secretion sexually dimorphic? - Riccardo Pofi, Jeremy W Tomlinson Lancet Diab Endocrinol
  There is no doubt that exposure to chronic, substantially elevated circulating cortisol levels increases morbidity and mortality, as shown by patients with established Cushing's syndrome.1 Adrenal adenomas are common and are often detected incidentally in apparently asymptomatic individuals. (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))
• 00:30
  [Articles] Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study - Timo Deutschbein, Giuseppe Reimondo, Guido Di Dalmazi, Irina Bancos, Jekaterina Patrova, Dimitra Argyro Vassiliadi, Anja Bara? Neki?, Miguel Debono, Pina Lardo, Filippo Ceccato, Luigi Petramala, Alessandro Prete, Iacopo Chiodini, Miomira Ivovi?, Kalliopi Pazaitou-Panayiotou, Krystallenia I Alexandraki, Felicia Alexandra Hanzu, Paola Loli, Serkan Yener, Katharina Langton, Ariadni Spyroglou, Tomaz Kocjan, Sabina Zacharieva, Nuria Valdés, Urszula Ambroziak, Mari Suzuki, Mario Detomas, Soraya Puglisi, Lorenzo Tucci, Danae Anastasia Delivanis, Dimitris Margaritopoulos, Tina Dusek, Roberta (...) Lancet Diab Endocrinol
  Cortisol autonomy is associated with increased all-cause mortality, particularly in women younger than 65 years. However, until results from randomised interventional trials are available, a conservative therapeutic approach seems to be justified in most patients with adrenal (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))

6 May

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Series] Management of menopause: a view towards prevention - Roger A Lobo, Anne Gompel Lancet Diab Endocrinol
  Women spend approximately one-third of their lives with menopause, which occurs around 50 years of age. It is now appreciated that several important metabolic and cardiovascular disease risks emerge during the menopausal transition. Many important conditions occur 10–15 years after menopause, (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))
• 00:30
  [Editorial] Menopause: a turning point for women's health - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  Rising demand for menopausal hormone therapy (MHT) in the UK has resulted in shortages of some products, as suppliers struggle to keep up with demand. A consequence of increasing awareness of menopause symptoms and treatment options among women, prescriptions for MHT in England have doubled in (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))

5 May

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 12:30
  [Series] Menopause: a cardiometabolic transition - Rossella E Nappi, Peter Chedraui, Irene Lambrinoudaki, Tommaso Simoncini Lancet Diab Endocrinol
  Menopause is often a turning point for women's health worldwide. Increasing knowledge from experimental data and clinical studies indicates that cardiometabolic changes can manifest at the menopausal transition, superimposing the effect of ageing onto the risk of cardiovascular disease. The (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))
• 00:30
  [In Focus] Hot topics on insulin access: the issue of thermostability - Talha Burki Lancet Diab Endocrinol
  Some 770 million people around the world do not have access to electricity. In the sprawling Democratic Republic of Congo, less than 9% of the population is on the energy grid; a third of rural households in Bangladesh are not connected to the power supply; and neighbouring Myanmar provides (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))

1 May

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:00
  [Correspondence] Methodological considerations in D-health cancer mortality results - Sam Egger, David P Smith, Visalini Nair-Shalliker Lancet Diab Endocrinol
  We thank Rachel Neale and colleagues1 for their publication of the D-health Trial results in The Lancet Diabetes & Endocrinology, and commend their efforts in conducting a large, population-based trial of vitamin D3 supplementation. We do, however, have some concerns about the cancer (...) (The Lancet Diabetes & Endocrinology 10, 5 (2022))
• 00:00
  [Correspondence] Methodological considerations in D-health cancer mortality results – Authors' reply - Rachel E Neale, Briony Duarte Romero, Donald S A McLeod, Dallas R English, Gunter Hartel, Jolieke C van der Pols, Alison J Venn, Penelope M Webb, David C Whiteman, Mary Waterhouse Lancet Diab Endocrinol
  We thank Sam Egger and colleagues for their interest in the results of the D-Health Trial.1 These authors raised the concern that missing underlying cause of death data could have biased our cancer mortality findings, and urged caution in drawing conclusions at this (...) (The Lancet Diabetes & Endocrinology 10, 5 (2022))

28 April

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Articles] Incidence rate patterns, cumulative incidence, and time trends for moderate and severe albuminuria in individuals diagnosed with type 1 diabetes aged 0–14 years: a population-based retrospective cohort study - Fanny Jansson Sigfrids, Per-Henrik Groop, Valma Harjutsalo Lancet Diab Endocrinol
  Our analyses show that the cumulative incidence of severe albuminuria has decreased between 1970–79 and 1980–99; however, whether this decrease solely denotes a delay in albuminuria, or also a true prevention of albuminuria, needs to be investigated further. Nevertheless, diabetic kidney disease (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))
• 00:30
  [Comment] The uncomfortable truth about kidney disease in type 1 diabetes - Bruce A Perkins Lancet Diab Endocrinol
  Decades ago, the renowned epidemiologists Andrzej Krolewski and James Warram, together with colleagues, drew attention to an uncomfortable truth: shockingly, even 50 years after the discovery of life-saving insulin, more than half of people diagnosed with type 1 diabetes died with kidney (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))

27 April

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Postsurgical radioiodine ablation in low-risk differentiated thyroid cancer - Furio Pacini Lancet Diab Endocrinol
  Since the first demonstration by Mazzaferri and colleagues1 that the administration of radioiodine therapy after total thyroidectomy for differentiated thyroid cancer reduced mortality and recurrences, such treatment strategy became the standard of care for patients with thyroid cancer. At that (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))

26 April

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Country Focus] Singapore's “War on Diabetes” - Yong Mong Bee, E Shyong Tai, Tien Y Wong Lancet Diab Endocrinol
  In 2016, in the face of an impending diabetes epidemic, Singapore started a new strategic campaign, announced by the then Minister of Health in a parliamentary speech, which was referred to as the “War on Diabetes”.1 This campaign sought to rally the entire nation to rein in the diabetes and (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))

23 April

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Articles] Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial - Tadej Battelino, Richard M Bergenstal, Angel Rodríguez, Laura Fernández Landó, Ross Bray, Zhentao Tong, Katelyn Brown Lancet Diab Endocrinol
  Once-weekly treatment with tirzepatide showed superior glycaemic control measured using CGM compared with insulin degludec in participants with type 2 diabetes on metformin, with or without a SGLT2 inhibitor. These new data provide additional evidence to the effect of tirzepatide and potential (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))
• 00:30
  [Articles] Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial - Tim Heise, Andrea Mari, J Hans DeVries, Shweta Urva, Jing Li, Edward John Pratt, Tamer Coskun, Melissa K Thomas, Kieren J Mather, Axel Haupt, Zvonko Milicevic Lancet Diab Endocrinol
  The glycaemic efficacy of GIP/GLP-1 receptor agonist tirzepatide in type 2 diabetes results from concurrent improvements in key components of diabetes pathophysiology, namely ?-cell function, insulin sensitivity, and glucagon secretion. These effects were large and help to explain the remarkable (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))
• 00:30
  [Comment] Tirzepatide adds hepatoprotection to its armoury - Giovanni Targher Lancet Diab Endocrinol
  In The Lancet Diabetes & Endocrinology, Amalia Gastaldelli and colleagues1 present their findings from SURPASS-3 MRI, a substudy of the randomised, open-label, parallel-group, phase-3 SURPASS-3 trial.2 It is the first study to date to assess the effect of a 52-week treatment with (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))
• 00:30
  [Comment] SURPASSing the current dogma: is our framework shifting? - Natasha P Malkani, Vanita R Aroda Lancet Diab Endocrinol
  In their article in The Lancet Diabetes and Endocrinology, Tadej Battelino and colleagues1 report on a dedicated substudy of the parent SURPASS-3 randomised clinical trial, in which all three groups given the dual GLP-1 and GIP, tirzepatide (5 mg, 10 mg, or 15 mg weekly doses), had (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))
• 00:30
  [Comment] Add-on value of tirzepatide versus semaglutide - André J Scheen Lancet Diab Endocrinol
  Type 2 diabetes is a complex disease with several key defects, including impaired insulin secretion, increased glucagon secretion, and insulin resistance, which is exacerbated by obesity. Thus, besides lifestyle measures, pharmacological therapy should aim to target most, if not all, of these (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))
• 00:30
  [Articles] Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial - Amalia Gastaldelli, Kenneth Cusi, Laura Fernández Landó, Ross Bray, Bram Brouwers, Ángel Rodríguez Lancet Diab Endocrinol
  Tirzepatide showed a significant reduction in LFC and VAT and ASAT volumes compared with insulin degludec in this subpopulation of patients with type 2 diabetes in the SURPASS-3 study. These data provide additional evidence on the metabolic effects of this novel dual GIP and GLP-1 receptor (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))

22 April

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Articles] Achievement of guideline recommended diabetes treatment targets and health habits in people with self-reported diabetes in India (ICMR-INDIAB-13): a national cross-sectional study - Ranjit Mohan Anjana, Ranjit Unnikrishnan, Mohan Deepa, Ulagamathesan Venkatesan, Rajendra Pradeepa, Shashank Joshi, Banshi Saboo, Ashok Kumar Das, Sarita Bajaj, Anil Bhansali, Sri Venkata Madhu, Vinay Kumar Dhandhania, Puthiyaveettil Kottayam Jabbar, Sunil M Jain, Arvind Gupta, Subhankar Chowdhury, Mohammed K Ali, Elangovan Nirmal, Radhakrishnan Subashini, Tanvir Kaur, Rupinder Singh Dhaliwal, Nikhil Tandon, Viswanathan Mohan, ICMR-INDIAB collaborators Lancet Diab Endocrinol
  Achievement of treatment targets and adoption of healthy behaviours remains suboptimal in India. Our results can help governments to adopt policies that prioritise improvement of diabetes care delivery and surveillance in India. (The Lancet Diabetes & Endocrinology 10, 6 (2022))
• 00:30
  [Comment] The ABC targets of diabetes in India - Jennifer Manne-Goehler Lancet Diab Endocrinol
  In April 2021, WHO announced the creation of a Global Diabetes Compact (GDC) initiative to address the increasingly urgent global diabetes epidemic. GDC aims to catalyse action on diabetes and specifically seeks to “boost efforts to prevent diabetes and bring treatment to all who need it.”1 To (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))
• 00:30
  [Comment] Decision making in differences of sex development/intersex care in the USA: bridging advocacy and family-centred care - David E Sandberg, Eric Vilain Lancet Diab Endocrinol
  “We now know this approach [early genital surgery] was harmful and wrong.”1 Two major US children's hospitals (Lurie Children's Hospital, Chicago, IL, and Boston Children's Hospital, Boston, MA) announced a suspension of some elective genital surgeries, particularly clitoroplasty. This (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))

8 April

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Editorial] Long COVID: the elephant in the room - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  On April 1, 2022, the UK government ended free universal COVID-19 testing, as part of the Living with COVID-19 plan. The legal requirement to isolate if positive has also been scrapped in England under this plan, and all other public health restrictions have now been (...) (The Lancet Diabetes & Endocrinology 10, 5 (2022))

6 April

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [In Focus] War in Ukraine ups demand for iodine pills - Talha Burki Lancet Diab Endocrinol
  An unexpected consequence of the Russian invasion of Ukraine, which began on Feb 24, 2022, has been the surge in demand for iodine pills in many European countries and others further afield. Online vendors have been selling tablets of potassium iodide, the salt of stable iodine, for twice their (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))

2 April

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Targeting PCSK9 inhibitors to those who will benefit most - Traci A Turner, Evan A Stein Lancet Diab Endocrinol
  In The Lancet Diabetes & Endocrinology, Petr Ostadal and colleagues report a post-hoc subgroup analysis of the ODYSSEY OUTCOMES trial assessing the contribution of metabolic risk factors to future cardiovascular events in patients with recent acute coronary syndrome.1 This large (...) (The Lancet Diabetes & Endocrinology 10, 5 (2022))
• 00:30
  [Comment] Dapagliflozin in young people with type 2 diabetes - Kalie L Tommerdahl, Robert G Nelson, Petter Bjornstad Lancet Diab Endocrinol
  The trial data presented by William V Tamborlane and colleagues, evaluating the effects of a novel adjunctive type 2 diabetes medication in young people (aged 18–24), provide an important therapeutic insight into this burgeoning, high-risk, and understudied population.1 Nearly 14 million people (...) (The Lancet Diabetes & Endocrinology 10, 5 (2022))
• 00:30
  [Comment] Breakthrough technology for in-hospital glucose monitoring - David Kerr, David Klonoff Lancet Diab Endocrinol
  75 years ago, the English physician and writer, Richard Asher, highlighted the physical and mental health risks associated with an admission to hospital.1 For people living with diabetes, they have both an increased risk of being admitted to hospital, and, once admitted, are likely to spend (...) (The Lancet Diabetes & Endocrinology 10, 5 (2022))
• 00:30
  [Articles] Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial - Petr Ostadal, Philippe Gabriel Steg, Yann Poulouin, Deepak L Bhatt, Vera A Bittner, Terrence Chua, Rafael Diaz, Shaun G Goodman, Yong Huo, Johan Wouter Jukema, Yuri Karpov, Robert Pordy, Michel Scemama, Michael Szarek, Harvey D White, Gregory G Schwartz, ODYSSEY OUTCOMES Investigators Lancet Diab Endocrinol
  Accumulation of metabolic risk factors was associated with higher risk of MACE in patients with recent acute coronary syndrome. Alirocumab reduced MACE consistently, but aRR increased with number of metabolic risk factors. (The Lancet Diabetes & Endocrinology 10, 5 (2022))
• 00:30
  [Articles] Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study - William V Tamborlane, Lori M Laffel, Naim Shehadeh, Elvira Isganaitis, Michelle Van Name, Jayantha Ratnayake, Cecilia Karlsson, Ensio Norjavaara Lancet Diab Endocrinol
  The primary outcome of change in HbA1c concentration was not significant in the intention-to-treat analysis of children, adolescents, and young adults with type 2 diabetes receiving dapagliflozin in addition to standard-of-care treatment. A prespecified sensitivity analysis of (...) (The Lancet Diabetes & Endocrinology 10, 5 (2022))

1 April

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:00
  [Correspondence] Data processing in the DMagic cluster randomised controlled trial - Edward Fottrell, Carina King, Kishwar Azad, on behalf of the DMagic Trial Team Lancet Diab Endocrinol
  Our Article1 in The Lancet Diabetes & Endocrinology provides evidence on the effectiveness of mHealth and Participatory Learning and Action (PLA) community mobilisation interventions for reducing population-level prevalence of intermediate hyperglycaemia and type 2 diabetes and the (...) (The Lancet Diabetes & Endocrinology 10, 4 (2022))
• 00:00
  [Corrections] Correction to Lancet Diabetes Endocrinol 2020; 8: 594–605 Lancet Diab Endocrinol
  Groeneweg S, van Geest FS, Abac? A, et al. Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study. Lancet Diabetes Endocrinol 2020; 8: 594–605—In this Article, Gautam P Ambegaonkar's name was spelt incorrectly. This correction has been made to the (...) (The Lancet Diabetes & Endocrinology 10, 4 (2022))
• 00:00
  [Corrections] Corrections to Lancet Diabetes Endocrinol 2022; 10: 120–28 Lancet Diab Endocrinol
  Neale RE, Baxter C, Duarte Romero B, et al. The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality. Lancet Diabetes Endocrinol 2022; 10: 120–28—In order to comply with requirements not to report small numbers of cases (n < 5), table S5 of the appendix of this (...) (The Lancet Diabetes & Endocrinology 10, 4 (2022))

29 March

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Country Focus] Diabetes in Pakistan: addressing the crisis - Zulfiqar A Bhutta, Zia Ul Haq, Abdul Basit Lancet Diab Endocrinol
  Population-based estimates for both type 1 and type 2 diabetes in low-income and middle-income countries are imprecise because of the paucity of registration and surveillance systems in these settings. Current estimates for diabetes prevalence are largely derived from the Global Burden of (...) (The Lancet Diabetes & Endocrinology 10, 5 (2022))

26 March

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Correspondence] Caring for people with diabetes and non-communicable diseases in Ukraine: a humanitarian emergency - Galyna Maystruk, Sigiriya Aebischer Perone, Valentyna Anufriyeva, Philippa Boulle, François Chappuis, Bruno Lab, David Beran Lancet Diab Endocrinol
  As war in Europe becomes a reality with the armed conflict in Ukraine, the global community has responded politically and economically, and is in the midst of preparing an large-scale humanitarian response. The first response needs to reach individuals who are directly affected by the conflict (...) (The Lancet Diabetes & Endocrinology 10, 5 (2022))

22 March

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Rising diabetes diagnosis in long COVID - K M Venkat Narayan, Lisa R Staimez Lancet Diab Endocrinol
  A few reports have raised the possibility that COVID-19 could increase the risk of type 2 diabetes.1,2 In The Lancet Diabetes & Endocrinology, Xie and Al-Aly3 offer further evidence for the increased risk of diabetes beyond the first 30 days of infection (post-acute phase) by analysing the (...) (The Lancet Diabetes & Endocrinology 10, 5 (2022))
• 00:30
  [Articles] Risks and burdens of incident diabetes in long COVID: a cohort study - Yan Xie, Ziyad Al-Aly Lancet Diab Endocrinol
  In the post-acute phase, we report increased risks and 12-month burdens of incident diabetes and antihyperglycaemic use in people with COVID-19 compared with a contemporary control group of people who were enrolled during the same period and had not contracted SARS-CoV-2, and a historical (...) (The Lancet Diabetes & Endocrinology 10, 5 (2022))

15 March

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Articles] Levothyroxine in euthyroid thyroid peroxidase antibody positive women with recurrent pregnancy loss (T4LIFE trial): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial - Myrthe M van Dijk, Rosa Vissenberg, Eric Fliers, Joris A M van der Post, Marie-Louise P van der Hoorn, Sabina de Weerd, Walter K Kuchenbecker, Annemieke Hoek, J Marko Sikkema, Harold R Verhoeve, Kimiko A Broeze, Corry H de Koning, Willem Verpoest, Ole B Christiansen, Carolien Koks, Jan P de Bruin, Dimitri N M Papatsonis, Helen Torrance, Madelon van Wely, Peter H Bisschop, Mariëtte Goddijn Lancet Diab Endocrinol
  Compared with placebo, levothyroxine treatment did not result in higher live birth rates in euthyroid women with recurrent pregnancy loss who were positive for TPO-Ab. On the basis of our findings, we do not advise routine use of levothyroxine in women who are TPO-Ab positive with recurrent (...) (The Lancet Diabetes & Endocrinology 10, 5 (2022))
• 00:30
  [Comment] Levothyroxine treatment in euthyroid women positive for thyroid peroxidase antibodies and recurrent pregnancy loss - Tim I M Korevaar, Rima Dhillon-Smith Lancet Diab Endocrinol
  Miscarriage matters. For couples who have a miscarriage, it is a devastating experience with major physical and psychological consequences that are often under—estimated or even trivialised.1 Combined with the major health-economic effect on a population level, this makes research into (...) (The Lancet Diabetes & Endocrinology 10, 5 (2022))

10 March

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Editorial] Ukraine: diabetes on the front line - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  The crisis in Ukraine is evolving rapidly, with 2 million people estimated to have fled the country as of March 8 and many more facing unimaginable danger and uncertainty. Despite some advances made in Ukraine's attempts to transform and modernise its health system, Ukrainian citizens still (...) (The Lancet Diabetes & Endocrinology 10, 4 (2022))

9 March

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Thank you to The Lancet Diabetes & Endocrinology clinical and statistical peer reviewers in 2021 - The Lancet Diabetes & Endocrinology Editors Lancet Diab Endocrinol
  Gail Adler (The Lancet Diabetes & Endocrinology 10, 4 (2022))

8 March

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Articles] The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020 - Margherita Pizzato, Mengmeng Li, Jerome Vignat, Mathieu Laversanne, Deependra Singh, Carlo La Vecchia, Salvatore Vaccarella Lancet Diab Endocrinol
  The current thyroid cancer epidemiological landscape is strongly suggestive of a large effect of overdiagnosis in many countries and settings worldwide, confirming the relevance of thyroid cancer overdiagnosis as a global public health (...) (The Lancet Diabetes & Endocrinology 10, 4 (2022))
• 00:30
  [Comment] Global thyroid estimates in 2020 - Livia Lamartina, Sophie Leboulleux, Isabelle Borget, Martin Schlumberger Lancet Diab Endocrinol
  Since the early 1980s, the incidence rate of thyroid cancers is increasing in many countries, although changes in mortality rates have been minimal.1–3 Reported in The Lancet Diabetes and Endocrinology, Margherita Pizzato and colleagues'4 used the GLOBOCAN database to estimate age-standardised (...) (The Lancet Diabetes & Endocrinology 10, 4 (2022))
• 00:30
  [Comment] Women in diabetes research: stepping towards equity - Linda A DiMeglio, Jamie R Wood, Eda Cengiz Lancet Diab Endocrinol
  “Real change, enduring change, happens one step at a time.”Ruth Bader Ginsburg (The Lancet Diabetes & Endocrinology 10, 4 (2022))

5 March

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] From preeclampsia to thyroid dysfunction: a long and winding road - Francesco Vermiglio, Mariacarla Moleti Lancet Diab Endocrinol
  Hypertensive disorders of pregnancy, including gestational hypertension and preeclampsia or eclampsia, affect around 10% of pregnant women and are one of the leading causes of maternal and neonatal mortality and morbidity worldwide.1 In addition, women with hypertension during pregnancy are at (...) (The Lancet Diabetes & Endocrinology 10, 4 (2022))
• 00:30
  [Comment] Creating diabetes guidelines for the individual not just the illness - Nuha Ali El Sayed, Robert Gabbay, Guillermo E Umpierrez Lancet Diab Endocrinol
  For more than 30 years the American Diabetes Association (ADA) has developed and published recommendations and related documents for clinical practice for diabetes care. ADA's Standards of Medical Care in Diabetes document,1 referred to as the Standards of Care, is intended to inform (...) (The Lancet Diabetes & Endocrinology 10, 4 (2022))
• 00:30
  [Articles] Association between maternal thyroid function and risk of gestational hypertension and pre-eclampsia: a systematic review and individual-participant data meta-analysis - Freddy J K Toloza, Arash Derakhshan, Tuija Männistö, Sofie Bliddal, Polina V Popova, David M Carty, Liangmiao Chen, Peter Taylor, Lorena Mosso, Emily Oken, Eila Suvanto, Sachiko Itoh, Reiko Kishi, Judit Bassols, Juha Auvinen, Abel López-Bermejo, Suzanne J Brown, Laura Boucai, Aya Hisada, Jun Yoshinaga, Ekaterina Shilova, Elena N Grineva, Tanja G M Vrijkotte, Jordi Sunyer, Ana Jiménez-Zabala, Isolina Riaño-Galan, Maria-Jose Lopez-Espinosa, Larry J Prokop, Naykky Singh Ospina, Juan P Brito, Rene Rodriguez-Gutierrez, Erik K Alexander, Layal Chaker, Elizabeth N Pearce, Robin P Peeters, Ulla (...) Lancet Diab Endocrinol
  Compared with euthyroidism, subclinical hypothyroidism during pregnancy was associated with a higher risk of pre-eclampsia. There was a U-shaped association of TSH with pre-eclampsia. These results quantify the risks of gestational hypertension or pre-eclampsia in women with thyroid function (...) (The Lancet Diabetes & Endocrinology 10, 4 (2022))

4 March

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Review] Obesity in children and adolescents: epidemiology, causes, assessment, and management - Hiba Jebeile, Aaron S Kelly, Grace O'Malley, Louise A Baur Lancet Diab Endocrinol
  This Review describes current knowledge on the epidemiology and causes of child and adolescent obesity, considerations for assessment, and current management approaches. Before the COVID-19 pandemic, obesity prevalence in children and adolescents had plateaued in many high-income countries (...) (The Lancet Diabetes & Endocrinology 10, 5 (2022))
• 00:30
  [Comment] The actual burden of obesity—accounting for multimorbidity - Avishai M Tsur, Gilad Twig Lancet Diab Endocrinol
  The prevalence of overweight and obesity is increasing worldwide, and this is forecast to continue in the coming years. One in two adults in the USA are projected to have obesity by 2030, and about one in four to have severe obesity.1 Excessive weight has been causally linked to diabetes, (...) (The Lancet Diabetes & Endocrinology 10, 4 (2022))
• 00:30
  [Articles] Body-mass index and risk of obesity-related complex multimorbidity: an observational multicohort study - Mika Kivimäki, Timo Strandberg, Jaana Pentti, Solja T Nyberg, Philipp Frank, Markus Jokela, Jenni Ervasti, Sakari B Suominen, Jussi Vahtera, Pyry N Sipilä, Joni V Lindbohm, Jane E Ferrie Lancet Diab Endocrinol
  Obesity is associated with diverse, increasing disease burdens, and might represent an important target for multimorbidity prevention that avoids the complexities of multitarget preventive regimens. (The Lancet Diabetes & Endocrinology 10, 4 (2022))

3 March

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Review] Osteoporosis in men - Tatiane Vilaca, Richard Eastell, Marian Schini Lancet Diab Endocrinol
  Osteoporosis in men is a common but often overlooked disorder by clinicians. The criterion for osteoporosis diagnosis in men is similar to that in women—namely, a bone mineral density (BMD) that is 2·5 standard deviations or more below the mean for the young adult population (aged 20–29 years; (...) (The Lancet Diabetes & Endocrinology 10, 4 (2022))

1 March

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Personal View] The relevance of T3 in the management of hypothyroidism - Domenico Salvatore, Tommaso Porcelli, Matthew D Ettleson, Antonio C Bianco Lancet Diab Endocrinol
  Levothyroxine monotherapy has been the standard of care for treatment of hypothyroidism for more than 40 years. However, patients treated with levothyroxine have relatively lower serum tri-iodothyronine (T3) concentrations than the general population, and symptoms of hypothyroidism persist for (...) (The Lancet Diabetes & Endocrinology 10, 5 (2022))
• 00:00
  [Correspondence] Dose–response relationships for vitamin D and all-cause mortality - Martin R Grübler, Heike A Bischoff-Ferrari, Stefan Pilz Lancet Diab Endocrinol
  The Emerging Risk Factors Collaboration/EPIC-CVD/Vitamin D Studies Collaboration1 report on a Mendelian meta-analysis of 500 962 participants, providing strong evidence that 25-hydroxyvitamin D (25[OH]D) concentrations below 40 nmol/L are causal for all-cause mortality. We congratulate the (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))
• 00:00
  [Correspondence] Dose–response relationships for vitamin D and all-cause mortality – Authors' reply - Stephen Burgess, Adam S Butterworth Lancet Diab Endocrinol
  We would like to thank Martin Grübler and colleagues for their correspondence regarding our published Article.1 In response to the points raised, regarding the threshold of 25-hydroxyvitamin D (25[OH]D) concentration, we would not want to be overly dogmatic about the specific threshold below (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))
• 00:00
  [Corrections] Correction to Lancet Diabetes Endocrinol 2022; 10: 102–11 Lancet Diab Endocrinol
  Fleseriu M, Dreval A, Bondar I, et al. Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol 2022; 10: 102–11—First, in the Discussion section (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))

18 February

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Review] A global view of the interplay between non-alcoholic fatty liver disease and diabetes - Norbert Stefan, Kenneth Cusi Lancet Diab Endocrinol
  Non-alcoholic fatty liver disease (NAFLD) has become an epidemic, much like other non-communicable diseases (NCDs), such as cancer, obesity, diabetes, and cardiovascular disease. The pathophysiology of NAFLD, particularly involving insulin resistance and subclinical inflammation, is not only (...) (The Lancet Diabetes & Endocrinology 10, 4 (2022))

12 February

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Editorial] Homing in on the causes of male infertility - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  Affecting millions of men and women of reproductive age worldwide, infertility (defined as the failure to conceive after 12 months of regular, unprotected sexual intercourse) deprives people of those most personal of choices—when to start a family and how many children to have. In addition, (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))
• 00:30
  [Editorial] Childhood cancer survival: a gap in need of closing - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  With a child dying from cancer every 3 min and survival as low as 20% in many low-income and middle-income countries (LMICs)—compared with 80% in most high-income countries—the need for children and adolescents with cancer to have better access to care could not be more apparent or urgent. (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))

9 February

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Data-driven type 2 diabetes patient clusters predict metabolic surgery outcomes - Jason Flannick Lancet Diab Endocrinol
  Optimism regarding precision medicine has increased in recent years, and type 2 diabetes provides one of its more promising applications.1 The large public health burden of type 2 diabetes is exacerbated by inadequate treatments, which might be better designed or deployed if the complex and (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))
• 00:30
  [Articles] Data-driven subgroups of type 2 diabetes, metabolic response, and renal risk profile after bariatric surgery: a retrospective cohort study - Violeta Raverdy, Ricardo V Cohen, Robert Caiazzo, Helene Verkindt, Tarissa Beatrice Zanata Petry, Camille Marciniak, Benjamin Legendre, Pierre Bauvin, Estelle Chatelain, Alain Duhamel, Elodie Drumez, Naima Oukhouya-Daoud, Mikael Chetboun, Gregory Baud, Emma Ahlqvist, Niels Wierup, Olof Asplund, Blandine Laferrère, Leif Groop, FranÇois Pattou Lancet Diab Endocrinol
  Patients in the SIRD subgroup had better outcomes after metabolic surgery, both in terms of type 2 diabetes remission and renal function, with no additional surgical risk. Data-driven classification might help to refine the indications for metabolic (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))

8 February

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [InFocus] Lebanon: insulin out of reach after subsidies lifted - Manjulika Das Lancet Diab Endocrinol
  People with diabetes face a critical situation in Lebanon, thanks to a substantial price hike of insulin. (The Lancet Diabetes & Endocrinology 10, 3 (2022))
• 00:30
  [Comment] Prevention of diabetes mortality at ages younger than 25 years: access to medications and high-quality health care - Henrik Toft Sørensen Lancet Diab Endocrinol
  Diabetes is one of the fastest growing chronic diseases in the world, with major effects on both people with diabetes and wider society. In 2019, worldwide diabetes prevalence was estimated at 9·3%.1 Although the global diabetes pandemic is largely due to type 2 diabetes, the incidence of type 1 (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))
• 00:30
  [Correspondence] An inter-humanitarian agency study of diabetes care and surveillance in humanitarian settings - Sylvia Kehlenbrink, Omar Mahboob, Sara Al-Zubi, Philippa Boulle, Sigiriya Aebischer Perone, Ahmad Hecham Alani, Lilian Kiapi, Laura Miller, Heiko Hering, Michael Woodman, Karen Donelan, Stephanie Kayden, Bianca C Porneala, Bernard Rosner, James B Meigs Lancet Diab Endocrinol
  Humanitarian crises and diabetes have been increasing at an unrelenting pace, especially in low-income and middle-income countries.1 Over 80% of the global displaced population live in low-income and middle-income countries, which host 81% of the global diabetes population.2 Furthermore, for (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))
• 00:30
  [Articles] Diabetes mortality and trends before 25 years of age: an analysis of the Global Burden of Disease Study 2019 - GBD 2019 Diabetes Mortality Collaborators Lancet Diab Endocrinol
  Decreasing diabetes mortality at ages younger than 25 years remains an important challenge, especially in low and low-middle SDI countries. Inadequate diagnosis and treatment of diabetes is likely to be major contributor to these early deaths, highlighting the urgent need to provide better (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))

5 February

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Steps to redressing an imbalance: GLP-1 analogues for obesity in east Asia - Tricia M-M Tan, Bernard Khoo Lancet Diab Endocrinol
  Obesity is a global disease and is particularly prevalent in Asia. 1 billion people across Asia are estimated to have a BMI exceeding 25 kg/m2.1 Obesity affects one in three Chinese individuals, with a marked increase observed in the past 15 years,2 this trend has also been observed in other (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))
• 00:30
  [Articles] Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial - Takashi Kadowaki, Joakim Isendahl, Usman Khalid, Sang Yeoup Lee, Tomoyuki Nishida, Wataru Ogawa, Kazuyuki Tobe, Toshimasa Yamauchi, Soo Lim, STEP 6 investigators Lancet Diab Endocrinol
  Adults from east Asia with obesity, with or without type 2 diabetes, given semaglutide 2·4 mg once a week had superior and clinically meaningful reductions in bodyweight, and greater reductions in abdominal visceral fat area compared with placebo, representing a promising treatment option for (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))

3 February

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [In Focus] Jennifer Manne-Goehler: at the crossroads of pandemics - Ray Cavanaugh Lancet Diab Endocrinol
  Increased awareness and distribution of antiretroviral treatments have tempered the catastrophe wrought by HIV/AIDS. But the same regions which suffered the heaviest HIV burden are now contending with a more recent public health crisis in the form of cardiovascular and metabolic diseases. The (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))

2 February

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [In Focus] Managing Diabetes and Homelessness - Talha Burki Lancet Diab Endocrinol
  It is difficult to overstate how complicated life becomes when you have nowhere to live. It is a situation increasing numbers of Londoners find themselves in. According to a new analysis by Shelter, a charity that campaigns to end homelessness and poor housing in the UK, 700 people sleep on the (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))

1 February

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Personal View] Sexual dimorphism in COVID-19: potential clinical and public health implications - Nicole Bechmann, Andreas Barthel, Andreas Schedl, Stephan Herzig, Zsuzsanna Varga, Catherine Gebhard, Manuel Mayr, Constanze Hantel, Felix Beuschlein, Christian Wolfrum, Nikolaos Perakakis, Lucilla Poston, Cynthia L Andoniadou, Richard Siow, Raul R Gainetdinov, Arad Dotan, Yehuda Shoenfeld, Geltrude Mingrone, Stefan R Bornstein Lancet Diab Endocrinol
  Current evidence suggests that severity and mortality of COVID-19 is higher in men than in women, whereas women might be at increased risk of COVID-19 reinfection and development of long COVID. Differences between sexes have been observed in other infectious diseases and in the response to (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))
• 00:00
  [Corrections] Correction to Lancet Diabetes Endocrinol 2022; 10: 142–48 Lancet Diab Endocrinol
  Lewis GF, Hegele RA. Effective, disease-modifying, clinical approaches to patients with mild-to-moderate hypertriglyceridaemia. Lancet Diabetes Endocrinol 2022; 10: 142–48—In the figure of this Personal View, the fifth bullet point should read “Treatment of diabetes…”. This correction has been made (...) (The Lancet Diabetes & Endocrinology 10, 2 (2022))

29 January

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Review] Bone fragility in diabetes: novel concepts and clinical implications - Lorenz C Hofbauer, Björn Busse, Richard Eastell, Serge Ferrari, Morten Frost, Ralph Müller, Andrea M Burden, Fernando Rivadeneira, Nicola Napoli, Martina Rauner Lancet Diab Endocrinol
  Increased fracture risk represents an emerging and severe complication of diabetes. The resulting prolonged immobility and hospitalisations can lead to substantial morbidity and mortality. In type 1 diabetes, bone mass and bone strength are reduced, resulting in up to a five-times greater risk (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))

13 January

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Editorial] The power of resilience - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  The world is under strain. At the time of writing, the number of confirmed COVID-19 deaths worldwide has passed 5·5 million. The highly transmissible omicron variant (B.1.1.529) is saturating hospitals and compromising the ability of health-care workers to provide quality care to all patients, (...) (The Lancet Diabetes & Endocrinology 10, 2 (2022))

11 January

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Maximising use of population data on cardiometabolic diseases - David Flood, David Guwatudde, Albertino Damasceno, Jennifer Manne-Goehler, Justine I Davies, Global Health and Population Project on Access to Care for Cardiometabolic Diseases (HPACC) Lancet Diab Endocrinol
  The worldwide burden of adult cardiometabolic diseases such as hypertension, diabetes, obesity, and dyslipidaemia continues its relentless increase. Scaling up the prevention, management, and control of cardiometabolic diseases is cost-effective but requires strong health systems.1 As we have (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))
• 00:30
  [Articles] The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality - Rachel E Neale, Catherine Baxter, Briony Duarte Romero, Donald S A McLeod, Dallas R English, Bruce K Armstrong, Peter R Ebeling, Gunter Hartel, Michael G Kimlin, Rachel O'Connell, Jolieke C van der Pols, Alison J Venn, Penelope M Webb, David C Whiteman, Mary Waterhouse Lancet Diab Endocrinol
  Administering vitamin D3 monthly to unscreened older people did not reduce all-cause mortality. Point estimates and exploratory analyses excluding the early follow-up period were consistent with an increased risk of death from cancer. Pending further evidence, the precautionary principle would (...) (The Lancet Diabetes & Endocrinology 10, 2 (2022))
• 00:30
  [Comment] Understanding decreasing mortality in people with diabetes - Jennifer Manne-Goehler, David Flood Lancet Diab Endocrinol
  In The Lancet Diabetes & Endocrinology, Dianna Magliano and colleagues1 assess trends in all-cause mortality from 1995 to 2016 among people with and without diabetes from 19 data sources in 16 high-income geographical areas. Using a pooled dataset including 21 million deaths over 0·5 billion (...) (The Lancet Diabetes & Endocrinology 10, 2 (2022))
• 00:30
  [Comment] Vitamin D supplementation and mortality - Inez Schoenmakers Lancet Diab Endocrinol
  In the Lancet Diabetes & Endocrinology, Rachel Neale and colleagues1 present their findings from D-Health, a population-based, double-blind, placebo-controlled vitamin D3 intervention trial in older Australian adults (n=21 315). It is the largest study to date to assess the effect of (...) (The Lancet Diabetes & Endocrinology 10, 2 (2022))
• 00:30
  [Articles] Trends in all-cause mortality among people with diagnosed diabetes in high-income settings: a multicountry analysis of aggregate data - Dianna J Magliano, Lei Chen, Bendix Carstensen, Edward W Gregg, Meda E Pavkov, Agus Salim, Linda J Andes, Ran Balicer, Marta Baviera, Juliana C N Chan, Yiling J Cheng, Helene Gardiner, Hanne L Gulseth, Romualdas Gurevicius, Kyoung Hwa Ha, György Jermendy, Dae Jung Kim, Zoltán Kiss, Maya Leventer-Roberts, Chun-Yi Lin, Andrea O Y Luk, Stefan Ma, Manel Mata-Cases, Didac Mauricio, Gregory A Nichols, Santa Pildava, Avi Porath, Stephanie H Read, Cynthia Robitaille, Maria Carla Roncaglioni, Paz Lopez-Doriga Ruiz, Kang-Ling Wang, Sarah H Wild, Naama Yekutiel, Jonathan E (...) Lancet Diab Endocrinol
  All-cause mortality in diabetes has decreased in most of the high-income countries we assessed. In eight of 19 data sources analysed, mortality decreased more rapidly in people with diabetes than in those without diabetes. Further longevity gains will require continued improvement in prevention (...) (The Lancet Diabetes & Endocrinology 10, 2 (2022))

8 January

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [In Focus] Money matters in the food choices we make - Talha Burki Lancet Diab Endocrinol
  Picky eaters pose a particular problem for impoverished households. If your son or daughter simply refuses to eat a certain food and you get it anyway, there is a fair chance that it will go to waste and your child will stay hungry. If that happens, you might not be able to find the money to (...) (The Lancet Diabetes & Endocrinology 10, 2 (2022))

1 January

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:00
  [Correspondence] Diabetes and the WHO Model List of Essential Medicines - Farah N Khan, Irl B Hirsch Lancet Diab Endocrinol
  The WHO Model List of Essential Medicines was first published in 1977 and includes minimum medicine needs for a basic health-care system, listing the most efficacious, safe, and cost-effective medicines for priority conditions.1 The goal of this list was to choose the medications that would be (...) (The Lancet Diabetes & Endocrinology 10, 1 (2022))
• 00:00
  [Correspondence] Diabetes and the WHO Model List of Essential Medicines - David Beran, Stéphane Besançon, Margaret Ewen, Edwin A M Gale, Maria Lazo-Porras, Molly Lepeska, Kasia Lipska, Jessica Zafra-Tanaka, Aigerim Zhaparova, John S Yudkin Lancet Diab Endocrinol
  The WHO Model List of Essential Medicines provides a core list of medicines that are safe, cost-effective, and necessary to address major public health concerns.1 Including long-acting insulin analogues on the WHO Model List of Essential Medicines emphasises global inequities in insulin but (...) (The Lancet Diabetes & Endocrinology 10, 1 (2022))
• 00:00
  [Correspondence] Diabetes and the WHO Model List of Essential Medicines - Thomas Danne, Francisco Javier Ampudia-Blasco, Chantal Mathieu Lancet Diab Endocrinol
  In September, 2021, WHO published the 22nd edition of its Model List of Essential Medicines, including insulin analogues and SGLT2 inhibitors.1 Insulin has been on WHO's Model List of Essential Medicines since it was first published in 1977. Although the 21st list, which was published in 2019, (...) (The Lancet Diabetes & Endocrinology 10, 1 (2022))
• 00:00
  [Correspondence] Diabetes and the WHO Model List of Essential Medicines - Ranjit Unnikrishnan, Viswanathan Mohan Lancet Diab Endocrinol
  Inadequately controlled diabetes costs the world more than US$800 million and 1·5 million deaths annually.1 Although the diabetologist's armamentarium has expanded to include many distinct classes of antidiabetic agents, inequities in access to diabetes treatments continue to pose a major (...) (The Lancet Diabetes & Endocrinology 10, 1 (2022))
• 00:00
  [Correspondence] Diabetes and the WHO Model List of Essential Medicines - Amulya Reddy Lancet Diab Endocrinol
  Médecins Sans Frontières welcomes the addition of insulin analogues and SGLT2 inhibitors to the 22nd WHO Model List of Essential Medicines1 as an opportunity to improve diabetes care globally. (The Lancet Diabetes & Endocrinology 10, 1 (2022))
• 00:00
  [Correspondence] Diabetes and the WHO Model List of Essential Medicines - Carissa F Etienne Lancet Diab Endocrinol
  Insulin was discovered 100 years ago—a groundbreaking finding that would earn Frederick Grant Banting and John James Rickard Macleod the Nobel Prize and radically change clinical outcomes and life expectancies for people with (...) (The Lancet Diabetes & Endocrinology 10, 1 (2022))
• 00:00
  [In Focus] Viswanathan Mohan: a dynasty of diabetology - Carl Power Lancet Diab Endocrinol
  Diabetes runs in some families but it's the study and treatment of diabetes that runs in Viswanathan Mohan's. His father, Moopil Viswanathan, earned himself the title of India's ‘father of diabetology.’ In 1948, he established the country's first diabetes clinic in post-independence India at the (...) (The Lancet Diabetes & Endocrinology 10, 1 (2022))
• 00:00
  [Corrections] Correction to Lancet Diabetes Endocrinol 2022; 10: 58–74 Lancet Diab Endocrinol
  Braune K, Lal RA, Petruželková L, et al. Open-source automated insulin delivery: international consensus statement and practical guidance for health-care professionals. Lancet Diabetes Endocrinol 2022: 10: 58–74—In this Review, the first sentence in the abstract should read “…are examples of (...) (The Lancet Diabetes & Endocrinology 10, 1 (2022))

23 December

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] How do clinicians integrate oral octreotide into their treatment plan for acromegaly? - Maya B Lodish Lancet Diab Endocrinol
  Since the late 1980s, injectable somatostatin receptor ligands (iSRLs) have been well established as treatment for acromegaly, and oral formulations of octreotide have more recently become available.1,2 In June, 2020, the US Food and Drug Administration approved the first oral octreotide (...) (The Lancet Diabetes & Endocrinology 10, 2 (2022))
• 00:30
  [Articles] Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial - Maria Fleseriu, Alexander Dreval, Irina Bondar, Gulnar Vagapova, Djuro Macut, Yulia G Pokramovich, Mark E Molitch, Nina Leonova, Gerald Raverot, Elena Grineva, Yury E Poteshkin, Yossi Gilgun-Sherki, William H Ludlam, Gary Patou, Asi Haviv, Murray B Gordon, Nienke R Biermasz, Shlomo Melmed, Christian J Strasburger Lancet Diab Endocrinol
  Oral octreotide was non-inferior to iSRL treatment, and might be a favourable alternative to iSRLs for many patients with acromegaly. (The Lancet Diabetes & Endocrinology 10, 2 (2022))
• 00:30
  [Review] Subclinical hypothyroidism in older individuals - Bernadette Biondi, Anne R Cappola Lancet Diab Endocrinol
  Subclinical hypothyroidism, which is defined as a thyroid-stimulating hormone concentration higher than the reference range (generally 4·5 mIU/L or higher) with normal free thyroxine concentrations, is frequently found in older individuals. International guidelines differ in recommendations for (...) (The Lancet Diabetes & Endocrinology 10, 2 (2022))

22 December

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] The pathogenesis, natural history, and treatment of type 1 diabetes: time (thankfully) does not stand still - Aaron W Michels, Maria J Redondo, Mark A Atkinson Lancet Diab Endocrinol
  “For time and the world do not stand still. Change is the law of life. And those who look only to the past or the present are certain to miss the future.”—John F Kennedy (The Lancet Diabetes & Endocrinology 10, 2 (2022))

21 December

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Nutrition-related health taxes: setting expectations - J Jaime Miranda, Anne-Marie Thow, María Kathia Cárdenas, Camila Corvalán, Tonatiuh Barrientos-Gutiérrez, Jay S Kaufman Lancet Diab Endocrinol
  The COVID-19 pandemic and the availability of effective vaccines have highlighted the need for robust evaluations of population health interventions, from vaccines to interventions for obesity. The robustness of these evaluations, and the identification of effective interventions, often rely on (...) (The Lancet Diabetes & Endocrinology 10, 2 (2022))

17 December

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Personal View] Effective, disease-modifying, clinical approaches to patients with mild-to-moderate hypertriglyceridaemia - Gary F Lewis, Robert A Hegele Lancet Diab Endocrinol
  Plasma triglyceride concentration is easily, inexpensively, and accurately measured, and when elevated is a highly informative disease marker that identifies individuals who frequently have a host of underlying metabolic, inflammatory, and atherogenic risk factors. Although this concept aligns (...) (The Lancet Diabetes & Endocrinology 10, 2 (2022))

16 December

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Correspondence] Dapagliflozin in patients with COVID-19: mind the kidneys – Authors' reply - Mikhail N Kosiborod, Russell Esterline, Jan Oscarsson, Samvel B Gasparyan, Remo H M Furtado, Subodh Verma, Otavio Berwanger Lancet Diab Endocrinol
  We appreciate the correspondence from Thiago Reis and colleagues regarding the selection of criteria for acute kidney injury in the DARE-19 trial.1 We used several definitions of kidney events in the trial, which were prespecified in the protocol approved by regulatory authorities in each (...) (The Lancet Diabetes & Endocrinology 10, 2 (2022))
• 00:30
  [Correspondence] Dapagliflozin in patients with COVID-19: mind the kidneys - Thiago Reis, Marlies Ostermann, Alexander Zarbock, John A Kellum, Claudio Ronco Lancet Diab Endocrinol
  We read the DARE-19 trial by Mikhail Kosiborod and colleagues,1 published in The Lancet Diabetes and Endocrinology with interest. The DARE-19 trial was a randomised, double-blind, placebo-controlled trial of patients hospitalised with COVID-19. Key inclusion criteria were hospitalisation with (...) (The Lancet Diabetes & Endocrinology 10, 2 (2022))

15 December

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [In Focus] Sufyan Hussain: co-creating possibilities - Ray Cavanaugh Lancet Diab Endocrinol
  Understanding and empathy for a patient's condition can take on a quantum leap of meaning when the physician is fighting the same battle. Sufyan Hussain has contended with type 1 diabetes for more than 30 years. He is also a consultant physician in diabetes and endocrinology, as well as an (...) (The Lancet Diabetes & Endocrinology 10, 2 (2022))

3 December

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Editorial] Childhood obesity: a growing pandemic - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  Childhood obesity rates have increased substantially over the past year in the UK, according to a new report from the UK Government's National Child Measurement Programme. This rise in prevalence is the largest single-year increase since the programme began 15 years ago and highlights the (...) (The Lancet Diabetes & Endocrinology 10, 1 (2022))

1 December

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Articles] Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial - Subodh Verma, Nitish K Dhingra, Javed Butler, Stefan D Anker, Joao Pedro Ferreira, Gerasimos Filippatos, James L Januzzi, Carolyn S P Lam, Naveed Sattar, Barbara Peil, Matias Nordaby, Martina Brueckmann, Stuart J Pocock, Faiez Zannad, Milton Packer, EMPEROR-Reduced trial committees and investigators Lancet Diab Endocrinol
  Empagliflozin reduced serious heart failure outcomes across doses and combinations of disease-modifying therapies for HFrEF. Clinically, these data suggest that empagliflozin might be considered as a foundational therapy in patients with HFrEF regardless of their existing background (...) (The Lancet Diabetes & Endocrinology 10, 1 (2022))
• 00:30
  [Articles] Trends in leading causes of hospitalisation of adults with diabetes in England from 2003 to 2018: an epidemiological analysis of linked primary care records - Jonathan Pearson-Stuttard, Yiling J Cheng, James Bennett, Eszter P Vamos, Bin Zhou, Jonathan Valabhji, Amanda J Cross, Majid Ezzati, Edward W Gregg Lancet Diab Endocrinol
  Diabetes leads to a wide range of established vascular and metabolic complications that has resulted in the implementation of diverse prevention programmes across high-income countries. Diabetes has also been associated with an increased risk of a broader set of conditions including cancers, (...) (The Lancet Diabetes & Endocrinology 10, 1 (2022))
• 00:30
  [Comment] The changing character of diabetes complications - Srikanth Bellary Lancet Diab Endocrinol
  Several factors influence the course of a chronic disease such as diabetes, including our understanding of the disease epidemiology, public health initiatives, and the introduction of new therapies and interventions. The cumulative effect of these factors is best studied by observations made (...) (The Lancet Diabetes & Endocrinology 10, 1 (2022))
• 00:30
  [Comment] Is the impact of add on heart failure therapy influenced by background therapy? - Lars Rydén, Giulia Ferrannini Lancet Diab Endocrinol
  Randomised clinical trials of novel pharmacological agents are essential to provide the highest level of evidence for medical treatments. Following careful evaluation, the results of such trials are incorporated into contemporary practice guidelines. The most recent guidelines on the management (...) (The Lancet Diabetes & Endocrinology 10, 1 (2022))
• 00:00
  [Review] Diagnosis and treatment of primary aldosteronism - Martin Reincke, Irina Bancos, Paolo Mulatero, Ute I Scholl, Michael Stowasser, Tracy Ann Williams Lancet Diab Endocrinol
  Primary aldosteronism is a common cause of secondary hypertension associated with excess cardiovascular morbidities. Primary aldosteronism is underdiagnosed because it does not have a specific, easily identifiable feature and clinicians can be poorly aware of the disease. The diagnostic (...) (The Lancet Diabetes & Endocrinology 9, 12 (2021))

30 November

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [In Focus] COVID-19 and diabetes in Africa: a lethal combination - Talha Burki Lancet Diab Endocrinol
  A new analysis by WHO has found that COVID-19 is four times deadlier in people with diabetes in Africa than it is for Africans without diabetes. WHO calculated case fatality rates from COVID-19 by comorbidity, across 13 nations in sub-Saharan Africa with a cumulative population of 270 million. (...) (The Lancet Diabetes & Endocrinology 10, 1 (2022))
• 00:30
  [Articles] Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials - Peter Rossing, Silvio E Inzucchi, Priya Vart, Niels Jongs, Kieran F Docherty, Pardeep S Jhund, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Scott D Solomon, David L DeMets, Olof Bengtsson, Magnus Lindberg, Anna Maria Langkilde, Mikaela Sjöstrand, Bergur V Stefansson, Cecilia Karlsson, Glenn M Chertow, Fan Fan Hou, Ricardo Correa-Rotter, Robert D Toto, David C Wheeler, John J V McMurray, Hiddo J L Heerspink, DAPA-CKD and DAPA-HF Trial Committees and (...) Lancet Diab Endocrinol
  Treatment with dapagliflozin reduced the incidence of new-onset type 2 diabetes in participants with chronic kidney disease and HF without a reduction in HbA1c. (The Lancet Diabetes & Endocrinology 10, 1 (2022))
• 00:30
  [Comment] SGLT-2 inhibitors: does it matter if they prevent type 2 diabetes - Alice Y Y Cheng Lancet Diab Endocrinol
  In 1736, Benjamin Franklin famously wrote “an ounce of prevention is worth a pound of cure”. This concept is particularly relevant in health care as the societal cost and burden of diseases and their treatments have grown exponentially. As of 2021, an estimated 537 million adults are living with (...) (The Lancet Diabetes & Endocrinology 10, 1 (2022))

26 November

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Telehealth for people with diabetes: poised for a new approach - Korey K Hood, Jessie J Wong Lancet Diab Endocrinol
  Telehealth has traditionally been viewed as the lesser of the two when compared to in-person health care. Studies on telehealth often compare a remote to an in-person approach and aim to achieve at least non-inferiority. This comparison implies that in-person health care is the gold standard, (...) (The Lancet Diabetes & Endocrinology 10, 1 (2022))

24 November

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Correspondence] Access to insulin and diabetes care in the Philippines - Michelle Ann B Eala, John Jefferson V Besa, Regiel Christian Q Mag-usara, Anna Elvira S Arcellana, Cecilia A Jimeno Lancet Diab Endocrinol
  Millions of people from low-income and middle-income countries (LMICs) are unable to access insulin and routine diabetes care.1 The Philippines, a lower-middle income country in southeast Asia with almost 4 million adults with diabetes,2 is no stranger to this crisis. Diabetes ranks fourth (...) (The Lancet Diabetes & Endocrinology 10, 1 (2022))

23 November

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Correspondence] Comparison of mortality in people with type 1 and type 2 diabetes by age of diagnosis: an incident population-based study in England and Wales - Naomi Holman, Sarah H Wild, Edward W Gregg, Jonathan Valabhji, Naveed Sattar, Kamlesh Khunti, National Diabetes Audit Research Group Lancet Diab Endocrinol
  Type 2 diabetes has traditionally been considered a disease of middle to later life. However, changes in lifestyle, particularly increases in obesity and physical inactivity, combined with increased screening have resulted in a growing number of diagnoses in childhood and early adulthood.1 (...) (The Lancet Diabetes & Endocrinology 10, 2 (2022))

19 November

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Correspondence] COVID-19 targets human adrenal glands - Waldemar Kanczkowski, Katja Evert, Marlena Stadtmüller, Martina Haberecker, Laura Laks, Lan-Sun Chen, Karl Frontzek, Jessica Pablik, Constanze Hantel, Felix Beuschlein, Thomas Kurth, Sven Gruber, Adriano Aguzzi, Zsuzsanna Varga, Stefan R Bornstein Lancet Diab Endocrinol
  COVID-19 develops due to infection with SARS-CoV-2, which particularly in elderly with certain comorbidities (eg, metabolic syndrome)1 can cause severe pneumonia and acute respiratory distress syndrome. Some patients with severe COVID-19 will develop a life-threatening sepsis with its typical (...) (The Lancet Diabetes & Endocrinology 10, 1 (2022))

16 November

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Review] Glycaemic management in diabetes: old and new approaches - Antonio Ceriello, Francesco Prattichizzo, Moshe Phillip, Irl B Hirsch, Chantal Mathieu, Tadej Battelino Lancet Diab Endocrinol
  HbA1c is the most used parameter to assess glycaemic control. However, evidence suggests that the concept of hyperglycaemia has profoundly changed and that different facets of hyperglycaemia must be considered. A modern approach to glycaemic control should focus not only on reaching and (...) (The Lancet Diabetes & Endocrinology 10, 1 (2022))

14 November

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Review] Open-source automated insulin delivery: international consensus statement and practical guidance for health-care professionals - Katarina Braune, Rayhan A Lal, Lenka Petruželková, Gary Scheiner, Per Winterdijk, Signe Schmidt, Linda Raimond, Korey K Hood, Michael C Riddell, Timothy C Skinner, Klemens Raile, Sufyan Hussain, OPEN International Healthcare Professional Network and OPEN Legal Advisory Group Lancet Diab Endocrinol
  Open-source automated insulin delivery systems, commonly referred to as do-it-yourself automated insulin delivery systems, are examples of user-driven innovations that were co-created and supported by an online community who were directly affected by diabetes. Their uptake continues to increase (...) (The Lancet Diabetes & Endocrinology 10, 1 (2022))

13 November

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Editorial] World Diabetes Day 2021: a time of reckoning - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  With the call to action “If not now, when?”, World Diabetes Day on Nov 14 marks the start of a 3-year “Access to Diabetes Care” campaign. Never more poignant than now—in this, the centenary of the discovery of insulin—the campaign is an opportunity to effect meaningful change in the lives of people (...) (The Lancet Diabetes & Endocrinology 9, 12 (2021))

9 November

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Opportunities and challenges in closed-loop systems in type 1 diabetes - Leah M Wilson, Peter G Jacobs, Michael C Riddell, Dessi P Zaharieva, Jessica R Castle Lancet Diab Endocrinol
  Commercial automated insulin delivery therapy can improve glucose outcomes by increasing glucose time-in-range (3·9–10·0 mmol/L; 70–180 mg/dL) and reducing hypoglycaemia ( (The Lancet Diabetes & Endocrinology 10, 1 (2022))

2 November

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Defining type 2 diabetes remission: KISS goodbye to confusion? - Shahrad Taheri Lancet Diab Endocrinol
  The concept that type 2 diabetes can revert to glycaemic levels below the diabetes threshold without diabetes medications (type 2 diabetes remission) is increasingly appreciated. Metabolic surgery results in a substantial proportion of people having type 2 diabetes remission, although the (...) (The Lancet Diabetes & Endocrinology 9, 12 (2021))
• 00:30
  [In Focus] PFAS: here today—here tomorrow - Talha Burki Lancet Diab Endocrinol
  There is no stronger bond in organic chemistry than the one between carbon and fluorine. Chains of carbon and fluorine, such as those that make up perfluoroalkyl and polyfluoroalkyl substances (PFAS), have a half-life measured in thousands of years. It is PFAS that make Teflon cooking utensils (...) (The Lancet Diabetes & Endocrinology 9, 12 (2021))

30 October

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Correspondence] Youth-onset type 2 diabetes among First Nations young people in northern Australia: a retrospective, cross-sectional study - Angela Titmuss, Elizabeth A Davis, Vicki O'Donnell, Mark Wenitong, Louise J Maple-Brown, Aveni Haynes, Hot North Diabetes in Youth Collaboration group Lancet Diab Endocrinol
  The prevalence of youth-onset type 2 diabetes, defined as that diagnosed before the age of 25 years, is increasing worldwide,1 particularly in marginalised, socioeconomically vulnerable, and First Nations communities.2,3 The pathophysiology, phenotype, comorbidities, complications, treatment (...) (The Lancet Diabetes & Endocrinology 10, 1 (2022))

28 October

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Targeting of vitamin D supplementation to individuals with deficiency - Guillaume Butler-Laporte, J Brent Richards Lancet Diab Endocrinol
  Vitamin D insufficiency and deficiency, as assessed by measurement of 25-hydroxyvitamin D (25[OH]D), is common in the population and safely correctable using inexpensive vitamin D tablets. Therefore, if low vitamin D levels cause disease, a tremendous opportunity exists to improve health (...) (The Lancet Diabetes & Endocrinology 9, 12 (2021))
• 00:30
  [Comment] Predicting diabetes risk in diverse populations: what next? - Josep M Mercader, Maggie C Y Ng, Alisa K Manning, Stephen S Rich Lancet Diab Endocrinol
  Diabetes is a major health problem of the 21st century, affecting 463 million individuals globally.1 Early identification of diabetes and therapy targeted to the individual can alter disease progression and reduce the risk of costly complications. The accuracy and utility of current prediction (...) (The Lancet Diabetes & Endocrinology 9, 12 (2021))
• 00:30
  [Articles] Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses - Emerging Risk Factors Collaboration/EPIC-CVD/Vitamin D Studies Collaboration Lancet Diab Endocrinol
  Stratified Mendelian randomisation analyses suggest a causal relationship between 25(OH)D concentrations and mortality for individuals with low vitamin D status. Our findings have implications for the design of vitamin D supplementation trials, and potential disease prevention (...) (The Lancet Diabetes & Endocrinology 9, 12 (2021))

22 October

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Revisiting osteoporosis guidelines - Ian R Reid Lancet Diab Endocrinol
  The past 5 years have seen the completion of several major trials of novel anti-osteoporosis drugs. The findings from these trials have resulted in the registration of romosozumab in many countries, registration of abaloparatide in the USA, and the abandonment of odanacatib. No advanced trials (...) (The Lancet Diabetes & Endocrinology 9, 12 (2021))

21 October

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Review] Consensus on diagnosis and management of Cushing's disease: a guideline update - Maria Fleseriu, Richard Auchus, Irina Bancos, Anat Ben-Shlomo, Jerome Bertherat, Nienke R Biermasz, Cesar L Boguszewski, Marcello D Bronstein, Michael Buchfelder, John D Carmichael, Felipe F Casanueva, Frederic Castinetti, Philippe Chanson, James Findling, Mônica Gadelha, Eliza B Geer, Andrea Giustina, Ashley Grossman, Mark Gurnell, Ken Ho, Adriana G Ioachimescu, Ursula B Kaiser, Niki Karavitaki, Laurence Katznelson, Daniel F Kelly, André Lacroix, Ann McCormack, Shlomo Melmed, Mark Molitch, Pietro Mortini, John Newell-Price, Lynnette Nieman, Alberto M Pereira, Stephan Petersenn, Rosario (...) Lancet Diab Endocrinol
  Cushing's disease requires accurate diagnosis, careful treatment selection, and long-term management to optimise patient outcomes. The Pituitary Society convened a consensus workshop comprising more than 50 academic researchers and clinical experts to discuss the application of recent evidence (...) (The Lancet Diabetes & Endocrinology 9, 12 (2021))

15 October

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Newer antidiabetic agents: at what price will they be cost effective? - Ranjit Unnikrishnan, Viswanathan Mohan Lancet Diab Endocrinol
  Type 2 diabetes is associated with substantial financial burden to patients and health-care systems around the world. Much of this burden is attributable to chronic complications of untreated diabetes, particularly those involving the cardiovascular system, kidneys, eyes, and feet. The (...) (The Lancet Diabetes & Endocrinology 9, 12 (2021))
• 00:30
  [Articles] Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis - Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC) Lancet Diab Endocrinol
  Among novel agents, SGLT2 inhibitors hold particular promise for reducing complications of diabetes and meeting common price targets, particularly when used among people with established cardiovascular or kidney disease. These findings are consistent with the choice to include SGLT2 inhibitors (...) (The Lancet Diabetes & Endocrinology 9, 12 (2021))

14 October

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Thought for food: a Cushing's syndrome enigma explained - Ashley Grossman Lancet Diab Endocrinol
  Just 21 years ago, most of the human genome was sequenced, and in the past 10 years in particular, the application of molecular techniques to human disease with this knowledge of the genome has led to an enormous increase in our understanding of the molecular basis of many diseases. This (...) (The Lancet Diabetes & Endocrinology 9, 12 (2021))
• 00:30
  [Articles] Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome: a multicentre, retrospective, cohort study - Fanny Chasseloup, Isabelle Bourdeau, Antoine Tabarin, Daniela Regazzo, Charles Dumontet, Nataly Ladurelle, Lucie Tosca, Larbi Amazit, Alexis Proust, Raphael Scharfmann, Tiphaine Mignot, Frédéric Fiore, Stylianos Tsagarakis, Dimitra Vassiliadi, Dominique Maiter, Jacques Young, Anne-Lise Lecoq, Vianney Deméocq, Sylvie Salenave, Hervé Lefebvre, Lucie Cloix, Philippe Emy, Rachel Dessailloud, Delphine Vezzosi, Carla Scaroni, Mattia Barbot, Wouter de Herder, François Pattou, Martine Tétreault, Gilles Corbeil, Margot Dupeux, Benoit Lambert, Gérard Tachdjian, Anne Guiochon-Mantel, Isabelle Beau, (...) Lancet Diab Endocrinol
  We propose that GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome results from a two-hit inactivation of KDM1A, consistent with the tumour suppressor gene model of tumorigenesis. Genetic testing and counselling should be offered to these patients and their (...) (The Lancet Diabetes & Endocrinology 9, 12 (2021))

7 October

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Editorial] The digital frontier: bringing one generation to the next - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  Oct 1 marked the UN International Day of Older Persons, which this year focused on Digital Equity for All Ages. The aim—to amplify the need for meaningful participation in the digital world by older persons—is more relevant and important now than ever before. During the COVID-19 pandemic, (...) (The Lancet Diabetes & Endocrinology 9, 11 (2021))
• 00:30
  [Editorial] Insulin analogues: two sides of the same coin - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  WHO's new Essential Medicines List (EML), updated on Oct 1, 2021, now includes long-acting insulin analogues and biosimilars for treatment of type 1 diabetes. (The Lancet Diabetes & Endocrinology 9, 11 (2021))

5 October

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Forecasting therapeutic responses by albuminuria and eGFR slope during the DAPA-CKD trial - Katherine R Tuttle Lancet Diab Endocrinol
  The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial is a landmark study that, along with a rapidly growing body of evidence, has firmly established SGLT2 inhibition as new standard of care for people with type 2 diabetes and chronic kidney disease.1,2 (...) (The Lancet Diabetes & Endocrinology 9, 11 (2021))
• 00:30
  [Articles] Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial - Hiddo J L Heerspink, Niels Jongs, Glenn M Chertow, Anna Maria Langkilde, John J V McMurray, Ricardo Correa-Rotter, Peter Rossing, C David Sjöström, Bergur V Stefansson, Robert D Toto, David C Wheeler, Tom Greene, DAPA-CKD Trial Committees and Investigators Lancet Diab Endocrinol
  Dapagliflozin significantly slowed long-term eGFR decline in patients with chronic kidney disease compared with placebo. The mean difference in eGFR slope between patients treated with dapagliflozin versus placebo was greater in patients with type 2 diabetes, higher HbA1c, and higher (...) (The Lancet Diabetes & Endocrinology 9, 11 (2021))
• 00:30
  [Articles] Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial - Niels Jongs, Tom Greene, Glenn M Chertow, John J V McMurray, Anna Maria Langkilde, Ricardo Correa-Rotter, Peter Rossing, C David Sjöström, Bergur V Stefansson, Robert D Toto, David C Wheeler, Hiddo J L Heerspink, DAPA-CKD Trial Committees and Investigators Lancet Diab Endocrinol
  In patients with chronic kidney disease with and without type 2 diabetes, dapagliflozin significantly reduced albuminuria, with a larger relative reduction in patients with type 2 diabetes. The similar effects of dapagliflozin on clinical outcomes in patients with or without type 2 diabetes, (...) (The Lancet Diabetes & Endocrinology 9, 11 (2021))
• 00:30
  [Review] COVID-19 and metabolic disease: mechanisms and clinical management - Charlotte Steenblock, Peter E H Schwarz, Barbara Ludwig, Andreas Linkermann, Paul Zimmet, Konstantin Kulebyakin, Vsevolod A Tkachuk, Alexander G Markov, Hendrik Lehnert, Martin Hrab? de Angelis, Hannes Rietzsch, Roman N Rodionov, Kamlesh Khunti, David Hopkins, Andreas L Birkenfeld, Bernhard Boehm, Richard I G Holt, Jay S Skyler, J Hans DeVries, Eric Renard, Robert H Eckel, K George M M Alberti, Bruno Geloneze, Juliana C Chan, Jean Claude Mbanya, Henry C Onyegbutulem, Ambady Ramachandran, Abdul Basit, Mohamed Hassanein, Gavin Bewick, Giatgen A Spinas, Felix Beuschlein, Rüdiger Landgraf, (...) Lancet Diab Endocrinol
  Up to 50% of the people who have died from COVID-19 had metabolic and vascular disorders. Notably, there are many direct links between COVID-19 and the metabolic and endocrine systems. Thus, not only are patients with metabolic dysfunction (eg, obesity, hypertension, non-alcoholic fatty liver (...) (The Lancet Diabetes & Endocrinology 9, 11 (2021))

1 October

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:00
  [Review] Obesity in people living with type 1 diabetes - Bart Van der Schueren, Darcy Ellis, Raquel N Faradji, Eeba Al-Ozairi, Jonathan Rosen, Chantal Mathieu Lancet Diab Endocrinol
  Although type 1 diabetes is traditionally considered a disease of lean people, overweight and obesity are becoming increasingly more common in individuals with type 1 diabetes. Non-physiological insulin replacement that causes peripheral hyperinsulinaemia, insulin profiles that do not match (...) (The Lancet Diabetes & Endocrinology 9, 11 (2021))

28 September

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Statins for Graves' orbitopathy: a new tool for prevention and treatment? - Luigi Bartalena, Eliana Piantanida, Maria Laura Tanda Lancet Diab Endocrinol
  Graves' orbitopathy, which affects about 25–30% of newly diagnosed patients with hyperthyroidism due to Graves' disease,1 is a multifactorial autoimmune disease causing inflammation and remodelling of orbital tissues, with relevant clinical manifestations heavily effecting the quality of life of (...) (The Lancet Diabetes & Endocrinology 9, 11 (2021))
• 00:30
  [Articles] Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial - Giulia Lanzolla, Elena Sabini, Marenza Leo, Francesca Menconi, Roberto Rocchi, Angela Sframeli, Paolo Piaggi, Marco Nardi, Claudio Marcocci, Michele Marinò Lancet Diab Endocrinol
  Addition of oral atorvastatin to an ivGC regimen improved Graves' orbitopathy outcomes in patients with moderate-to-severe, active eye disease who were hypercholesterolaemic. Future phase 3 studies, which could potentially recruit patients regardless of low-density lipoprotein cholesterol (...) (The Lancet Diabetes & Endocrinology 9, 11 (2021))

25 September

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Impact of the COVID-19 pandemic on transgender and gender diverse health care - Claire M Burgess, Abagail W Batchelder, Colleen A Sloan, Michael Ieong, Carl G Streed Lancet Diab Endocrinol
  Transgender and gender diverse individuals experience pervasive invalidation and discrimination in our society. Gender-minority stressors, including gender-related stigma and discrimination, increase vulnerability to health problems (as compared with cisgender peers) resulting in disparities in (...) (The Lancet Diabetes & Endocrinology 9, 11 (2021))

25 August

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Review] Adrenal myelolipomas - Jan Calissendorff, Carl Christofer Juhlin, Anders Sundin, Irina Bancos, Henrik Falhammar Lancet Diab Endocrinol
  Adrenal myelolipomas are benign, lipomatous tumours with elements of myeloid cells, most of which present as adrenal incidentalomas and comprise 3·3–6·5% of all adrenal masses. Adrenal myelolipomas are usually unilateral (in 95% of cases), variable in size, most often found during midlife, and (...) (The Lancet Diabetes & Endocrinology 9, 11 (2021))

6 August

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [In Focus] Sherita Hill Golden: tackling the source of health disparities - Ray Cavanaugh Lancet Diab Endocrinol
  “So much of what influences metabolic health occurs outside of the clinical and health-care context”, says Sherita Hill Golden, the Hugh P McCormick Family Professor of endocrinology and metabolism at Johns Hopkins Medicine (Baltimore, MD, USA), where she also serves as Vice President and Chief (...) (The Lancet Diabetes & Endocrinology 9, 11 (2021))